Consensus Omeros Corporation

Stocks

OMER

US6821431029

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 24/10/2026 am IST			5-day change	1st Jan Change
16.57 ^USD	-1.72%		+2.28%	-3.52%

16/10	Omeros Shares Fall After Narsoplimab Application Rejected Again by EU Agency	MT
16/10	Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Friday Amid Investor Caution	MT

Evolution of the Average Target: Omeros Corporation

Evolution of the Target Price: Omeros Corporation

Changes in Analyst Recommendations: Omeros Corporation

51d4875b5.aKUpTtvqf0t31OYCIt3-bs0BuVvbdtDDWOnpB3wF8Ks.Hf9oGp--CSdG4IoxY7m4L7RC7ij2Mr-vbdiaXjhHyZgE5FwquMcLLCO2jQ~88e7de0d7f7c70dd34a29e6df7270507

Analysts' recommendations: Omeros Corporation

22/09	Omeros Shares Rise After Cantor Fitzgerald Upgrade	MT
22/09	Cantor Fitzgerald Upgrades Omeros to Overweight From Neutral, Price Target is $22	MT
15/25/15	Omeros Shares Surge Pre-Bell After Asset Purchase, License Deal With Novo Nordisk	MT
10/25/10	HC Wainwright Initiates Coverage on Omeros With Buy Rating, $9 Price Target	MT
15/23/15	UBS Adjusts Omeros Price Target to $4 From $2, Maintains Neutral Rating	MT
08/22/08	UBS Downgrades Omeros to Neutral From Buy, Adjusts Price Target to $2 From $12	MT
09/22/09	BofA Securities Downgrades Omeros to Underperform Rating From Neutral, Price Target is $3	MT
08/22/08	BofA Securities Downgrades Omeros to Neutral From Buy, Sets $4 Price Target	MT
18/22/18	Cantor Fitzgerald Adjusts Omeros' Price Target to $20 From $34, Reiterates Overweight Rating	MT
19/21/19	Omeros : HC Wainwright Adjusts Price Target on Omeros to $12 From $19, Maintains Buy Rating	MT
15/21/15	Omeros : UBS Adjusts Price Target on Omeros to $13 From $25 on Drug Filing Deficiencies, Maintains Buy Rating	MT
11/21/11	Omeros : Wedbush Suspended Coverage on Omeros	MT
08/21/08	Omeros : JPMorgan Downgrades Omeros to Underweight from Neutral	MT
06/21/06	Omeros : HC Wainwright Adjusts Omeros' Price Target to $19 from $32, Keeps Buy Rating	MT
04/21/04	Omeros : Maxim Downgrades Omeros to Hold from Buy	MT
02/21/02	Omeros : Wedbush Downgrades Omeros to Underperform From Neutral, Lowers PT to $5 From $18 After FDA Delays PDUFA For Narsoplimab	MT
01/21/01	Omeros : Maxim Group Downgrades Omeros to Hold From Buy	MT
27/21/27	Omeros : JPMorgan Starts Omeros at Neutral With $15 Price Target	MT
18/21/18	Omeros : WBB Securities Reinstates Omeros With Strong Buy, $100 Price Target	MT
26/21/26	Omeros : HC Wainwright Adjusts Omeros' Price Target to $32 From $34, Keeps Buy Rating	MT
01/21/01	Omeros : UBS Starts Omeros at Buy With $25 Price Target	MT
20/21/20	Omeros : HC Wainwright Adjusts Omeros' Price Target to $34 from $31, Keeps Buy Rating	MT
20/21/20	Omeros : Wedbush Adjusts Omeros' Price Target to $18 From $13, Maintains Neutral Rating	MT
04/20/04	Omeros : Maxim Adjusts Omeros' Price Target to $25 from $20, Keeps Buy Rating	MT
17/20/17	Omeros : Wedbush Adjusts Omeros' Price Target to $13 From $12, Maintains Neutral Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	OMEROS CORPORATION					+65.96%
	WUXI APPTEC CO., LTD.					+32.59%
	ARGENX SE					+28.07%
	LONZA GROUP AG					+10.26%
	IQVIA HOLDINGS INC.					+8.34%
	BEONE MEDICINES AG					+15.58%
	REVOLUTION MEDICINES, INC.					+38.43%
	CELLTRION, INC.					+38.53%
	WUXI BIOLOGICS (CAYMAN) INC.					+31.23%
	GENMAB A/S					+4.99%
	Average					+27.40%
	Weighted average by Cap.					+23.48%